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Transcriptome analysis of a rat polycystic kidney disease
(PKD) model: importance of genes involved in extracellular
matrix metabolism. PKD is a common genetic cause of
chronic renal failure, and is characterized by the
accumulation of fluid-filled cysts in the kidneys and other
organs. Abnormalities in the expression of selected genes
thought to be involved in cystogenesis have been described,
but no systematic analysis of the global transcriptomal
pattern has been reported. With this aim, a rat
oligomicroarray was used to identify variations in gene
expression in Han:Sprague–Dawley Cy/Cy rats, an animal
model presenting a severe PKD phenotype. Some
upregulated genes were validated using real-time
polymerase chain reaction in Cy/Cy and Cy/þ rats. Among
the 350 genes identified as being upregulated, we found
about 30 genes involved in extracellular matrix metabolism.
These genes encoded proteins or peptides that could be
implicated into two different biological processes: molecules
involved in fibrosis and proteins involved in adhesion to the
extracellular matrix. In heterozygotes, some genes (glypican
3, fibronectin 1) were already upregulated in early stages of
the disease. We conclude that differential regulation of
genes linked to extracellular matrix metabolism may be
one of the first events leading to tubule enlargement and
subsequent cyst formation in PKD.
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Autosomal-dominant polycystic kidney disease (PKD) and
the other genetic forms of cystic kidney disease are
responsible for more than 5% of the worldwide total of
end-stage renal failure cases.1 Despite the identification of the
genes responsible for these diseases and the elucidation of
numerous key events in the development of PKD, particularly
the role of the primary cilium, there is still no treatment
available for PKD patients. Detailed knowledge of the
different pathways associated with the progression of renal
failure in autosomal-dominant PKD will undoubtedly
provide new therapeutic avenues for the management of
this condition.
PKD may be caused by different mechanisms, genetic or
not, and is characterized by a progressive evolution involving
the following phases. The first phase involves dilatation of
the tubules. Subsequently, invaginations appear within the
dilated tubules, followed by the formation of cysts, which
are no longer related to the original tubule. The growth of
the cysts characterizes the final phase.1 The formation and
growth of large numbers of cysts leads to chronic renal failure
and ultimately end-stage renal failure.
Although the histopathology of the progression of the
disorder has been described in detail, few data are available
regarding the potential role of variations in gene expression
in the progression of PKD. Moreover, most of these data
concern only part of the cellular and tissue-specific
transcriptome.2 Grace of the international efforts in genome
and EST sequencing, most of the transcriptional units
have been identified in the three most commonly used
mammalian systems: humans, mice and rats.3,4 This has
allowed the performance of large-scale transcriptional
analysis in these models.
We have performed a transcriptional analysis of normal
and polycystic kidneys, in order to track changes in gene
expression that may be associated with cystic disease. Our
strategy was to use total kidneys, in order to represent the
natural situation as closely as possible. This choice was
dictated by the difficulty of culturing kidney cystic cells, and
to avoid the possibility of artefactual transcriptional changes
associated with the in vitro culture conditions necessary for
the promotion of kidney cell growth. Obviously, our
biological samples are not homogeneous in term of their
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constituent tissues, but in situ hybridization may be used
to refine the analysis, as well as immunocytochemistry on
tissues sections.
In order for our analysis to be significant, it was necessary
to use a model in which the number of cysts per kidney was
high. For this reason, we have chosen Han:Sprague–Dawley
(SPRD) rats, a model of inherited polycystic kidney
disorder.5,6 The gene involved in this disorder is located on
chromosome 5, but has not yet been isolated.7 Han:SPRD
rats provide a model of severe PKD, and homozygotes (Cy/
Cy) usually die within the first month after birth. Hetero-
zygotes (Cy/þ ) develop a progressive autosomal-dominant
PKD in which cysts appear after 2 to 3 months of life, and
increase in number and size throughout the lifespan.6
Variations in the expression of genes involved in several
signalling pathways have been previously described in this
model.8–11 These different pathways have been confirmed in
other models or in the human disease.12–14 Hence, despite the
lack of identification of the mutant gene, Han:SPRD rats
provide insights into human autosomal-dominant PKD.
RNAs from normal and Cy/Cy homozygote rats were
used to perform a transcriptomal analysis using rat
oligonucleotide microarrays. We observed that a large
number genes involved in extracellular matrix metabolism
were overexpressed. We also used some of this information to
describe variations in gene expression related to progression
of the disease in Cy/þ rats. Here, we report these data
and discuss the potential impact of these variations in terms
of two important events in PKD: fibrosis and loss of
adherence to cell matrix.
RESULTS AND DISCUSSION
In order to identify variations in gene expression associated
with PKD, RNAs were extracted from the kidneys of normal
and 3-week-old Cy/Cy rats and a transcriptomal analysis was
performed using rat oligomicrochips. For the synthesis of the
probes used in the initial screen, RNA samples from the
normal rats were labelled with Cy3 and those from Cy/Cy rats
with Cy5. In a reciprocal experiment, the same samples were
labelled in the inverse sense, that is, a dye-swap approach.
Genes that were found to be over- or underexpressed in
the initial screen and that behaved in a reciprocal manner
in the second screen (e.g. underexpressed in the first screen
and overexpressed in the second screen) were selected and
included in a minilibrary. The expression profiles of these
genes were then compared to hybridization data from four
different microarrays hybridized with RNAs originating from
four different Cy/Cy animals. The reference sample was the
RNA isolated from the wild-type littermates used in the first
two screening experiments. Genes that maintained their
expression profiles in the initial dye-swap experiment as well
as the subsequent microarray screens were analyzed in more
detail; this final subset of differentially regulated genes
represented more than 90% of those selected for inclusion
in the dye-swap minilibrary. A total of 440 genes presented
variations in their expression profiles with a P-valueo0.05 as
predicted by the bioinformatic software; of these, 350 were
upregulated and 90 were downregulated.
We then grouped these genes according to their molecular
function, and evaluated the percentage on these different
groups present in the up- and downregulated genes sets
(Figure 1). Three different functional categories of genes
present in the upregulated group were of particular interest
to us: the cytoskeletal/structural genes, the extracellular
matrix genes, and the cell communication genes. As the
frequency of these groups of genes in the transcriptome of
Cy/Cy rats is higher than the expected frequency in
transcriptome of normal animals, we chose to focus on this
aspect. To note, the relevance of fibrotic processes in PKD
disease has been discussed extensively.15–17 We observed that
around 30 genes with either a structural function or a role in
extracellular matrix protein synthesis or degradation were
overexpressed in the kidneys of the Cy/Cy animals (Table 1).
Interestingly, these genes could be further separated into
two different biological processes. The first comprises
genes involved in fibrosis. These encode either signalling
proteins, such as connective tissue growth factor (CTGF) or
transforming growth factor-b (TGF-b) or small peptides
such as dermatan sulfate proteoglycan-II, glypican, and
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Figure 1 | Gene classification by their molecular function. Genes
identified as either up- or downregulated were classified according to
the information obtained from Gene Ontology and compared with
the classification in normal rat kidney transcriptome. Percentages
were calculated using the total numbers of up- or downregulated
genes. (a) Groups of upregulated genes. (b) Sets of downregulated
genes. An asterisk indicates the molecular function groups that
highly differ from overall normal rat transcriptome and up/down-
regulated transcripts. Only three classes, all upregulated in
pathological kidneys, diverge from the normal distribution.
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syndecan.18–21 The second category represents genes corres-
ponding to proteins associated with cell migration and
adhesion during embryonic/morphogenetic processes, such
as fibronectin 1 (Fn1), integrin alpha v subunit, and collagen
XII.22 Finally, a series of genes encoding metalloproteases that
are involved in extracellular matrix protein proteolysis were
also found to be overexpressed.23–25 Surprisingly, almost
none of the genes identified as being downregulated were
found to be associated with extracellular matrix protein
metabolism.
In order to verify these data, we performed real-time
polymerase chain reaction (RT-PCR) analysis on RNAs from
Cy/Cy and þ /þ rats. Analyzed genes were chosen among
which are shown the highest and the lowest fold change
values. An example is shown in Figure 2. We found that all
the genes tested presented similar variations in their
expression patterns upon either microarray screening or
RT-PCR analysis (Table 2), thereby validating the expression
data obtained from the initial microarray screens.
As our data related to only the most severely affected
animals (Cy/Cy), we also analyzed RNAs for the CTGF,
glypican 3, syndecan 1 (Sdc1), Fn1 and dermatan sulfate
proteoglycan-II genes in 1-, 3-, and 8-month-old Cy/þ rats
using the real-time PCR assay. We correlated the expression
profiles of these genes with the pathophysiology of the disease
by measuring the serum creatinine levels of the animals over
the period of the experiment. Figure 3 shows the levels of
serum creatinine in the Cy/þ animals throughout their
lifespan. At 4–6 months, the animals presented the first signs
of renal failure, and their kidney function was dramatically
impaired by 8 months of age. As cyst progression has already
been described in this model by means of histological
analysis,6 few studies have used serum creatinine levels as a
marker of renal function.
Table 1 | Relevant upregulated genes in Cy/Cy rats, identified using rat oligo-microarrays, divided into molecular function
categories
Sequence description P-value Fold change
Extracellular matrix proteins
Cytoplasmic linker 2 (Cyln2) 8.11E04 1.48
Glycoprotein (transmb) nmb (Gpnmb) 1.82E11 2.40
Vimentin (Vim) 2.70E08 1.99
Lectin galactose-inding, soluble 3 (Lgals3) 1.50E05 1.68
Transmembrane 4 (Tm4sf3) 4.57E09 2.08
Integrin alpha v subunit 4.86E05 1.73
Syndecan 1 (Sdc1) 2.82E06 1.53
Glypican 3 (Gpc3) 6.80E6 1.71
Collagen XVIII 1.65E05 1.67
Collagen XII alpha 1 (Col12a1) 1.71E04 1.56
Leucyl-spc. aminopeptidase PILS (APPILS) 1.16E04 1.52
Fibromodulin (Fmod) 2.09E10 2.26
Biglycan (Bgn) 8.65E06 1.70
Dermatan sulfate proteoglycan-II (decorin) 1.51E07 1.90
Fibronectin 1 (Fn1) 2.88E04 1.53
Matrix Gla protein (Mgp) 2.46E06 1.76
Extracellular matrix protein 2 (Ecm2) 0.00E+00 1.31
Fibrinogen, gamma polypeptide (Fgg) 3.04E12 2.51
Matrix protein metabolism
Matrix metalloproteinase 14, m-inserted (Mmp14) 6.82E05 1.43
Matrix metalloproteinase 7 (matrilysin) (Mmp7) 1.72E08 2.12
Tissue inhibitor of Mmp 2 (Timp2) 4.25E06 1.74
A disintegrin and metalloproteinase with thrombospondin motifs 1 (ADAMTS-1) 2.84E04 1.53
Ser (or cys) proteinase inhibitor, clade E, member 1 (Serpine1) 3.04E09 2.14
Cathepsin D (Ctsd) 7.68E09 2.06
Cathepsin K (Ctsk) 1.67E08 2.04
Ser (or Cys) proteinase inhibitor (PAI) 3.04E09 2.14
Lysozyme (Lyz) 1.05E08 2.04
Cell–cell communication
Interferon gamma receptor (Ifngr) 3.66E07 1.86
Tumor necrosis factor receptor (Tnfr1) 2.16E07 1.89
Connective tissue growth factor (Ctgf) 7.37E13 2.60
Latent TGF beta-inding protein 2 (Ltbp2) 1.71E12 2.55
Latent TGF beta-inding protein 1 (Ltbp1) 6.52E04 1.36
TGF-b-timulated clone 22 (Tgfb1i4) 8.36E11 1.81
TGF-b2 (Tgfb2) 1.03E05 1.71
Neuregulin 1 (Nrg1) 3.34E04 1.57
Ciliary neurotropic factor (Cntf) 2.27E05 1.67
Fold changes indicated the logarithm of the ratio in intensities of hybridization of the Cy/Cy versus the normal kidney RNAs. The P-values were calculated by the Rosetta
software, taking into account the relative intensites as well as the ratio of these intensities.
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From expression data presented in Table 3, we were able to
divide the genes tested into two categories. The expression
of the genes involved in inflammation/fibrosis (CTGF and
dermatan sulfate proteoglycan-II) was only slightly increased
in the Cy/þ males at 1 month of age. However, the
expression of these genes increased significantly with
the onset of renal failure and followed the progression of
the disorder. Fn1, Sdc1, and glypican 3 expressions were
increased in the male heterozygotes at 1 and 3 months of age,
before the appearance of cysts and/or the onset of renal
failure. These genes are clearly involved in developmental
processes. Fn1 is a major player in early embryonic stages
and cell migration,26 whereas glypican-3 is implicated in
Simpson–Golabi–Behmel syndrome and has recently been
linked to renal development.27,28
What do these results tell us in terms of the pathophysio-
logy of the renal cystic disorders? They indicate the
occurrence of two types of events. The first requires the
genes encoding the proteins or peptides involved in
inflammatory processes and fibrosis. It has long been known
that fibrosis and necrosis are associated with the cystic
disorders.29 Moreover, abundant fibrosis has been described
in the Han:SPRD rat.30 Although it is difficult to deduce
from these observations which event may trigger the onset of
fibrosis, it is generally assumed that the expression of CTGF,
dermatan sulfate proteoglycan-II, and Sdc1 is stimulated by
TGF-b, which may be the initial event in this whole process.31
Stimulation of the expression of TGF-b itself could be
owing to an increase in the cAMP pool, as has already been
described.32 Interestingly, the expression of these genes
increased with progression of the disorder, indicating a
link between this increase and progression of the fibrosis.
Furthermore, the increase in expression of these genes is low
in young Cy/þ animals, where few cysts are detected,
indicating that fibrosis/inflammation occurs at a later stage,
and may be linked to the increase in the number and size of
the cysts seen during disease progression.
The second type of event involves the extracellular matrix
proteins linked to morphogenic processes. It is possible that
variations in the expression of these proteins may be involved
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Figure 2 | Quantitative PCR. (a and b) Amplification plots for the
CTGF and glypican 3 cDNAs. #Amplification curves for Rps29, the
housekeeping gene: *Amplification curves for the test gene in Cy/Cy
rats. **Amplification curves for the test gene in normal rats (þ /þ ).
(c) Relative amounts of the mRNAs of several genes in Cy/Cy rats.
Table 2 | Real-time PCR validation of the microarray results
DDCT in Cy/Cy rats
relative to normal (+/+)
Relative quantity
Cy/Cy versus (+/+) P-value
CTGF 3.2070.20 11.3771.61 0.0143
Fn1 0.8870.14 1.8470.17 0.0143
Sdc1 1.9570.12 3.8570.32 0.0143
Decorin 1.6470.13 3.1170.18 0.0143
Gpc3 2.6770.13 6.3570.59 0.0143
CTGF=connective tissue growth factor; decorin=dermatan sulfate proteoglycan-II;
Fn1=fibronectin 1; Gpc3=glypican 3; Sdc1=syndecan 1.
The same RNAs samples, originating from Cy/Cy or normal rat kidneys, were
subjected to real-time PCR quantification, using specific primers corresponding to
the genes identified as being overexpressed in the microarray experiments (see
Materials and Methods). The expression of selected genes was compared to that of
Rps29. Results were expressed related to those of the normal rats (+/+). DDCT
indicates the logarithm of the relative ratio of the hybridization signal between Cy/
Cy versus normal rats. Relative quantity represents the ratio, in terms of numbers of
molecules, between the two samples. The P-value indicates the statistical
significance of these results.
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Figure 3 | Serum creatinine profile evolution in Cy/þ rats during
the lifespan follow-up. Numbers on the X-axis represent the ages of
animals in months. The basal levels calculated from þ /þ animals are
represented by the control column.
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in the loss of adhesion of tubular cells to the matrix, leading
to dilatation of the tubules and subsequent cyst formation.
These genes may thus be good candidates for one of the first
events that occur during the asymptomatic phase of PKD,
a stage that is currently poorly understood. Interestingly,
variation in gene expression is high in young Cy/þ rats, and
for Fn1, no variation was seen during the progression of the
disorder. This could be an indication that upregulation
of these genes is an early event that could be linked leading to
cyst formation.
In conclusion, if similar variations in gene expression
can be validated in other PKD models, we propose that
the genes that we have identified in this study will prove to
be appropriate targets for new rational therapies for this
disorder.
MATERIALS AND METHODS
Animals and tissue samples
Han:SPRD rats were obtained from Dr N Gretz and were kept in our
local core animal facility. At 3 weeks of age, before the Cy/Cy rats
usually die, males were anesthetized with isoflurane and their
kidneys were removed and snap-frozen in liquid nitrogen. Clear
morphological evidence led us to choose Cy/Cy animals, but
DNA analysis was used for genotyping Cy/þ and þ /þ rats. DNA
samples were isolated from hair specimens, and were then geno-
typed by amplification using the d5rat9 primers (UniSTS: 122170;
127–136 bp)33 Kidneys from male Cy/þ and þ /þ rats were also
obtained at 1, 3, and 8 months of age (five in each group). In
order to assess renal function in Cy/þ rats over their lifespan,
blood samples were collected from their tail veins and the
plasma creatinine levels were determined using an autoanalyzer
(Olympus AU400).
RNA extraction and analysis
After pulverization of the renal tissue in liquid nitrogen, total RNA
was extracted using Trizol in accordance with the manufacturer’s
instructions. The quality and concentration of each sample was
tested using an Agilent 2100 bioanalyzer. Five samples were prepared
for each group (þ /þ , Cy/þ , and Cy/Cy).
Hybridization and microarray scanning
The following materials were purchased from Agilent Technologies,
France: the Low RNA Input fluorescent linear amplification
kit (5185-818), the in situ hybridization kit Plus (5184-568), and
the 60-mer rat oligomicroarray kit (G4130A) (for additional
information on the oligomicroarrays visit www.agilent.com). The
reverse transcription labelling reactions and hybridizations essen-
tially followed the protocol recommended by Agilent Technologies.
Briefly, a 10 mg aliquot of each total RNA sample was reverse
transcribed into a cDNA probe using an oligo(dT) primer.
The reaction was carried out in a solution containing 500 mM dNTP
and 400 U MMLV reverse transcriptase at 401C for 2 h, and then
terminated by incubation at 651C for 15 min. The reverse trans-
cription and incorporation reactions were performed at 401C for 2 h
in a mixture containing either 400 mM cyanine 3-carbamylated
protein (Cy3; for the þ /þ samples) or 400mM cyanine 5-carb-
amylated protein (Cy5; for the Cy/Cy samples), the transcription
mix, and T7 RNA polymerase. For purification of the amplified
labelled cRNA samples, RNeasy spin columns (Qiagen, SA, France)
were used according to the manufacturer’s protocol. Hybridization
was carried out in 440ml of a mixture containing 750 ng of Cy3-and
Cy5-labelled cRNA probes, control targets, and the fragmented DNA
supplied by the manufacturer at 601C for 17 h. The microarrays were
then washed according to the manufacturer’s protocol, dried, and
scanned using an Agilent microarray scanner with a 532 nm laser for
Cy3 measurement and a 635 nm laser for Cy5 measurement. The
results were analyzed using a Luminator bioinformatics platform
(Rosetta Inc., Rosetta Biosoftware, WA, USA).
Reverse transcriptase-PCR analysis
To confirm the differential gene expression patterns, we observed
between the Cy/Cy and þ /þ animals, we selected five upregulated
genes, namely, CTGF, Fn1, Sdc1, dermatan sulfate proteoglycan-II,
and glypican 3, and verified their levels of expression by quantitative
reverse transcriptase-PCR using an ABI PRISM 7700 sequence
detection system. The housekeeping gene Rps29 was used for data
normalization.34 The results were treated using the comparative CT
method, where the amount of the target, normalized to the
endogenous reference and relative to a calibrator, is given by
2DDCT We also followed the changes in the expression of these genes
in Cy/þ rats of 1, 3, and 8 months of age.
Statistical analysis
The reverse transcriptase-PCR data were analyzed with the non-
parametric Mann–Whitney test owing to the small number of
samples. We used the Prism v4 software to perform the statistical
analysis.
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